Regenerative focus Opportunity to partner or co-develop regenerative medicine platforms leveraging Frequency’s progenitor cell activation approach, with potential tie-ins to remyelination therapies for multiple sclerosis.

Preclinical to clinical Sales angle around enabling translational collaborations as Frequency advances its lead preclinical program toward clinical applications, offering access to early-stage research tools, platforms, and regulatory pathways.

Strategic merger potential Consider targeting conversations around post-merger integration services, IP strategy, or collaborative programs with Korro Bio to expand portfolio breadth in regenerative biology and accelerate go-to-market potential.

Hearing and neurotech overlap Identify cross-sell opportunities with firms focused on inner ear regeneration and sensorineural therapies, given Frequency’s prior exploration of hair cell regeneration and the broader neuroregenerative ecosystem.

Funding and scaling Approach with clinical development services, manufacturing development support, or strategic funding partnerships to help scale preclinical programs, leveraging Frequency’s established public company presence and funding history.